Phil Taylor at pharmaphorum | Contact Details

Media Database

>

Phil Taylor

Contact this person

Email address

p*****@*******.comGet email address

Influence score

32

Phone

(XXX) XXX-XXXX Get mobile number

Location

United Kingdom

Languages

English

Covering topics

General Assignment News
Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place

Sign up for free

Recent Articles

pharmaphorum.com

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC - pharmaphorum

FDA’s ODAC doesn’t vote on AstraZeneca’s perioperative Imfinzi regimen in NSCLC but has deep reservations about the design of the phase 3 trial supporting it

over 1 year ago

pharmaphorum.com

Study finds wearables deliver key insights in heart disease - pharm...

Consumer wearables have shown a benefit when used to monitor treatment responses in patients with atrial fibrillation and heart failure.

over 1 year ago

pharmaphorum.com

IT outage raises resilience, security concerns in healthcare - phar...

As healthcare systems try to recover from major outage event, attention turns to potential fraud and resiliency concerns

over 1 year ago

pharmaphorum.com

Re-elected von der Leyen pledges EU measures for biotech - pharmaph...

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

over 1 year ago

pharmaphorum.com

Call goes out for simpler clinical trial regulation in UK - pharmap...

Framework governing early-stage clinical trials in the UK is stifling research and needs to be simplified, says BJCP paper

over 1 year ago

pharmaphorum.com

Novo leads $100m financing for Alzheimer's player Asceneuron - phar...

Novo Holdings leads $100m financing for Swiss biotech Asceneuron, which is developing an oral tau therapy for Alzheimer’s disease

over 1 year ago

pharmaphorum.com

UK’s Destiny Pharma hops on the AIM delisting train - pharmaphorum

Destiny Pharma has joined a growing list of UK biotech companies seeking to delist from the AIM exchange and return to private ownership

over 1 year ago

pharmaphorum.com

Investors take issue with Taisho Pharma’s buyout price - pharmaphorum

Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court

over 1 year ago

pharmaphorum.com

Flagship closes $3.6bn biotech fund, with a focus on AI - pharmaphorum

Flagship Pioneering raises $3.6bn to fund around 25 startups in human health, sustainability and AI, with $1bn set aside for strategic partnerships

over 1 year ago

pharmaphorum.com

Study finds GLP-1 drugs may cut obesity-related cancers - pharmaphorum

GLP-1 agonists like Novo Nordisk’s Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

over 1 year ago

pharmaphorum.com

NHS will take more than one term to fix, says Streeting - pharmaphorum

After Labour landslide in UK general election, former shadow health secretary West Streeting sets out his objectives for the NHS.

over 1 year ago

pharmaphorum.com

Private equity firms 'eyeing $20bn for Sanofi consumer unit' - phar...

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business

over 1 year ago

pharmaphorum.com

Study links Ozempic/Wegovy to sight-threatening disorder - pharmaph...

A study of Novo Nordisk’s semaglutide has found a possible link between the diabetes and obesity drug and a rare condition that causes sight loss.

over 1 year ago

pharmaphorum.com

UK gets guidance on synthetic human embryos for research - pharmaph...

A UK code of practice has been drawn up to make sure that research on human embryo models derived from stem cells is carried out ethically and responsibly.

over 1 year ago

pharmaphorum.com

Judge kicks out another Medicare price negotiation challenge - phar...

A Connecticut federal judge has rejected Boehringer Ingelheim’s challenge to Medicare’s drug price negotiation programme

over 1 year ago

pharmaphorum.com

House committee backs some Medicare cover for obesity drugs - pharm...

House Committee has voted in favour of a bill that would end a 20-year restriction on the coverage of drugs to treat obesity under Medicare

over 1 year ago

pharmaphorum.com

FDA reveals diversity action plan guide for clinical trials - pharm...

FDA publishes its long-awaited guidance on diversity action plans for clinical trials.

over 1 year ago

pharmaphorum.com

England, Denmark back CSL's haemophilia B gene therapy - pharmaphorum

CSL Behring’s gene therapy Hemgenix for haemophilia B has been backed for reimbursement in England and Denmark.

over 1 year ago

pharmaphorum.com

Mistrust in healthcare is hitting clinical trial enrolment - pharma...

Pharma industry execs say mistrust in healthcare in the US is a barrier to efforts to improve diversity in clinical trials.

over 1 year ago

pharmaphorum.com

BMS gets FDA approval for Krazati in colorectal cancer - pharmaphorum

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer.

over 1 year ago

pharmaphorum.com

NWEH says module cuts side effect reporting burden in trials - phar...

NWEH launches software that takes legwork out of serious adverse event reporting in clinical trials and could reduce costs.

over 1 year ago

Phil Taylor

News Editor at pharmaphorum

View more media outlets and journalists by signing up to Prowly

Recent Articles